The estimated Net Worth of Joseph Michael Burnett is at least $5.06 Milión dollars as of 6 March 2024. Mr Burnett owns over 23,704 units of ClearPoint Neuro Inc stock worth over $3,350,790 and over the last 7 years he sold CLPT stock worth over $1,109,516. In addition, he makes $596,513 as Pres a CEO & Director at ClearPoint Neuro Inc.
Mr has made over 8 trades of the ClearPoint Neuro Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 23,704 units of CLPT stock worth $289,426 on 6 March 2024.
The largest trade he's ever made was selling 25,000 units of ClearPoint Neuro Inc stock on 21 June 2021 worth over $464,250. On average, Mr trades about 3,563 units every 57 days since 2017. As of 6 March 2024 he still owns at least 274,430 units of ClearPoint Neuro Inc stock.
You can see the complete history of Mr Burnett stock trades at the bottom of the page.
Joseph Michael Burnett is the Pres, CEO & Director at ClearPoint Neuro Inc.
As the Pres a CEO & Director of ClearPoint Neuro Inc, the total compensation of Mr Burnett at ClearPoint Neuro Inc is $596,513. There are no executives at ClearPoint Neuro Inc getting paid more.
Mr Burnett is 44, he's been the Pres a CEO & Director of ClearPoint Neuro Inc since . There are 2 older and 1 younger executives at ClearPoint Neuro Inc. The oldest executive at ClearPoint Neuro Inc is Dr. Paul A. Bottomley, 67, who is the Advisor.
Joseph's mailing address filed with the SEC is C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100, SOLANA BEACH, CA, 92075.
Over the last 12 years, insiders at ClearPoint Neuro Inc have traded over $1,109,516 worth of ClearPoint Neuro Inc stock and bought 529,405 units worth $775,964 . The most active insiders traders include Lynnette C Fallon, Michael Pietrangelo a R John Fletcher. On average, ClearPoint Neuro Inc executives and independent directors trade stock every 93 days with the average trade being worth of $207,411. The most recent stock trade was executed by Lynnette C Fallon on 14 May 2024, trading 17,153 units of CLPT stock currently worth $209,438.
we are a medical device company that develops and commercializes innovative platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or mri, guidance. since our inception in 1998, we have focused on research and product development in the field of interventional mri. from 1998 to 2002, we deployed significant resources to fund our efforts to develop the foundational capabilities for enabling mri-guided interventions and to build an intellectual property position. in 2003, our focus shifted to identifying and building out commercial applications for the technologies we developed in prior years. we have two product platforms. our clearpoint® system, which is in commercial use in the united states, is used to perform minimally invasive surgical procedures in the brain. our cleartrace system, which is still in development, will be used to perform minimally invasive surgical procedures in the heart. bot
ClearPoint Neuro Inc executives and other stock owners filed with the SEC include: